Literature DB >> 18679822

Congenital disorder of glycosylation type Id (CDG Id): phenotypic, biochemical and molecular characterization of a new patient.

A Rimella-Le-Huu1, H Henry, I Kern, S Hanquinet, E Roulet-Perez, C J Newman, A Superti-Furga, L Bonafé, D Ballhausen.   

Abstract

Congenital disorders of glycosylation (CDG) are a family of multisystem inherited disorders caused by defects in the biosynthesis of N- or O-glycans. Among the many different subtypes of CDG, the defect of a mannosyltransferase encoded by the human ALG3 gene (chromosome 3q27) is known to cause CDG Id. Six patients with CDG Id have been described in the literature so far. We further delineate the clinical, biochemical, neuroradiological and molecular features of CDG Id by reporting an additional patient bearing a novel missense mutation in the ALG3 gene. All patients with CDG Id display a slowly progressive encephalopathy with microcephaly, severe psychomotor retardation and epileptic seizures. They also share some typical dysmorphic features but they do not present the multisystem involvement observed in other CDG syndromes or any biological marker abnormalities. Unusually marked osteopenia is a feature in some patients and may remain undiagnosed until revealed by pathological fractures. Serum transferrin screening for CDG should be extended to all patients with encephalopathy of unknown origin, even in the absence of multisystem involvement.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18679822     DOI: 10.1007/s10545-008-0959-x

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  12 in total

Review 1.  The skeletal manifestations of the congenital disorders of glycosylation.

Authors:  D Coman; M Irving; P Kannu; J Jaeken; R Savarirayan
Journal:  Clin Genet       Date:  2008-05-06       Impact factor: 4.438

2.  Congenital disorder of glycosylation type Id: clinical phenotype, molecular analysis, prenatal diagnosis, and glycosylation of fetal proteins.

Authors:  Jonas Denecke; Christian Kranz; Juergen Ch von Kleist-Retzow; Kristin Bosse; Peter Herkenrath; Otfried Debus; Erik Harms; Thorsten Marquardt
Journal:  Pediatr Res       Date:  2005-07-08       Impact factor: 3.756

3.  Congenital disorder of glycosylation id presenting with hyperinsulinemic hypoglycemia and islet cell hyperplasia.

Authors:  Liangwu Sun; Erik A Eklund; Wendy K Chung; Chao Wang; Jason Cohen; Hudson H Freeze
Journal:  J Clin Endocrinol Metab       Date:  2005-04-19       Impact factor: 5.958

4.  CDG-Id caused by homozygosity for an ALG3 mutation due to segmental maternal isodisomy UPD3(q21.3-qter).

Authors:  E Schollen; S Grünewald; L Keldermans; B Albrecht; C Körner; G Matthijs
Journal:  Eur J Med Genet       Date:  2005-02-17       Impact factor: 2.708

5.  Congenital disorders of glycosylation: rapidly enlarging group of (neuro)metabolic disorders.

Authors:  Stephanie Grünewald
Journal:  Early Hum Dev       Date:  2007-10-24       Impact factor: 2.079

6.  An activated 5' cryptic splice site in the human ALG3 gene generates a premature termination codon insensitive to nonsense-mediated mRNA decay in a new case of congenital disorder of glycosylation type Id (CDG-Id).

Authors:  Jonas Denecke; Christian Kranz; Dirk Kemming; Hans-Georg Koch; Thorsten Marquardt
Journal:  Hum Mutat       Date:  2004-05       Impact factor: 4.878

Review 7.  Congenital disorders of glycosylation: review of their molecular bases, clinical presentations and specific therapies.

Authors:  T Marquardt; J Denecke
Journal:  Eur J Pediatr       Date:  2003-03-15       Impact factor: 3.183

8.  Carbohydrate-deficient glycoprotein syndrome--a fourth subtype.

Authors:  H Stibler; U Stephani; U Kutsch
Journal:  Neuropediatrics       Date:  1995-10       Impact factor: 1.947

9.  CDG-Id in two siblings with partially different phenotypes.

Authors:  Christian Kranz; Liangwu Sun; Erik A Eklund; Donna Krasnewich; Janet R Casey; Hudson H Freeze
Journal:  Am J Med Genet A       Date:  2007-07-01       Impact factor: 2.802

Review 10.  Congenital disorders of glycosylation--a challenging group of IEMs.

Authors:  J Vodopiutz; O A Bodamer
Journal:  J Inherit Metab Dis       Date:  2008-04-04       Impact factor: 4.982

View more
  6 in total

1.  ALG3-CDG: lethal phenotype and novel variants in Chinese siblings.

Authors:  Yue Bian; Chong Qiao; ShuGuang Zheng; Hao Qiu; Huan Li; ZhiTao Zhang; ShaoWei Yin; HongKun Jiang; Jesse Li-Ling; CaiXia Liu; Yuan Lyu
Journal:  J Hum Genet       Date:  2020-07-12       Impact factor: 3.172

2.  Classical Galactosaemia and CDG, the N-Glycosylation Interface. A Review.

Authors:  Ashwini Maratha; Hugh-Owen Colhoun; Ina Knerr; Karen P Coss; Peter Doran; Eileen P Treacy
Journal:  JIMD Rep       Date:  2016-08-09

3.  Successful treatment of intractable epilepsy with ketogenic diet therapy in twins with ALG3-CDG.

Authors:  C Paketci; P Edem; S Hiz; E Sonmezler; D Soydemir; G Sarikaya Uzan; Y Oktay; E O'Heir; S Beltran; S Laurie; A Töpf; H Lochmuller; R Horvath; U Yis
Journal:  Brain Dev       Date:  2020-05-07       Impact factor: 1.961

4.  Expanding the phenotype, genotype and biochemical knowledge of ALG3-CDG.

Authors:  Hind Alsharhan; Bobby G Ng; Earnest James Paul Daniel; Jennifer Friedman; Eniko K Pivnick; Amal Al-Hashem; Eissa Ali Faqeih; Pengfei Liu; Nicole M Engelhardt; Kierstin N Keller; Jie Chen; Pamela A Mazzeo; Jill A Rosenfeld; Michael J Bamshad; Deborah A Nickerson; Kimiyo M Raymond; Hudson H Freeze; Miao He; Andrew C Edmondson; Christina Lam
Journal:  J Inherit Metab Dis       Date:  2021-03-01       Impact factor: 4.750

Review 5.  ALG3-CDG: a patient with novel variants and review of the genetic and ophthalmic findings.

Authors:  Martina Farolfi; Anna Cechova; Nina Ondruskova; Jana Zidkova; Bohdan Kousal; Hana Hansikova; Tomas Honzik; Petra Liskova
Journal:  BMC Ophthalmol       Date:  2021-06-05       Impact factor: 2.209

Review 6.  Insights into complexity of congenital disorders of glycosylation.

Authors:  Sandra Supraha Goreta; Sanja Dabelic; Jerka Dumic
Journal:  Biochem Med (Zagreb)       Date:  2012       Impact factor: 2.313

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.